Systematic review investigating the relationship between autism spectrum disorder and metabolic dysfunction.
Autistic clients carry extra risk for metabolic syndrome and type 2 diabetes—screen them early.
01Research in Context
What this study did
Beck et al. (2021) hunted every paper that checked blood sugar, blood pressure, lipids, or weight in autistic people. They set strict rules: only human studies published before 2021. The final pile gave a birds-eye view of how often metabolic problems show up.
What they found
Across studies, autistic people had higher rates of high blood sugar, high blood pressure, and type 2 diabetes than non-autistic groups. The numbers varied a lot, so the team warns the risk is real but not yet nailed down to a single figure.
How this fits with other research
Correia et al. (2006) and Burack et al. (2004) already spotted mitochondrial and carnitine glitches in autistic kids. Y’s review folds these older pieces into the bigger metabolic puzzle.
Gulati et al. (2026) found higher homocysteine and dityrosine in children, hinting at oxidative stress. Y’s review links this pattern to the wider metabolic-syndrome picture.
Esteban-Figuerola et al. (2019) and Çıtar Dazıroğlu et al. (2024) show autistic kids eat fewer protective nutrients. Y’s paper says poor diet may feed the metabolic risk, so food data and lab data now point the same way.
Why it matters
You now have a red-flag checklist: glucose, lipids, blood pressure, and diet quality. Add these to your intake forms and annual physical referrals. Early screens can catch silent diabetes or hypertension before it stalls progress in therapy sessions.
Want CEUs on This Topic?
The ABA Clubhouse has 60+ free CEUs — live every Wednesday. Ethics, supervision & clinical topics.
Join Free →Add a one-page metabolic-risk questionnaire to intake packets and flag any yes answers for physician follow-up.
02At a glance
03Original abstract
The objective of this systematic review is to examine metabolic dysfunction, specifically metabolic syndrome and its components, as well as type 2 diabetes mellitus (T2DM) as it relates to individuals with a diagnosis of Autism Spectrum Disorder (ASD). We searched PubMed, Embase, Cochrane, PsychInfo, and Scopus from January 1, 1998 to October 12, 2018 for English, peer-reviewed, original articles containing adult and pediatric populations with any form of ASD and metabolic dysfunction, including T2DM, hyperglycemia, hypertension, dyslipidemia, or central obesity. Exclusion criteria included studies without ASD-specific results, basic science research, review papers, case studies, and medication clinical trials. Eight studies were included in this review, with a total of 70,503 participants with ASD and 2,281,891 in comparison groups. Within ASD populations, higher prevalence for metabolic syndrome components hyperglycemia, hypertension, and dyslipidemia were observed, as well as increased incidence and prevalence of T2DM. However, heterogeneity of study definitions and measurements should be noted. While there is evidence of increased prevalence of T2DM, hyperglycemia, hypertension, and dyslipidemia for those with ASD, the relationship is poorly understood. There is also lack of research investigating central obesity and risk of metabolic syndrome as a diagnosis. More research addressing these gaps is warranted to evaluate the risk of metabolic dysfunction in populations with ASD.
Research in autism spectrum disorders, 2021 · doi:10.1038/s41598-017-12003-4